多西他塞与奥沙利铂分别联合替吉奥治疗晚期胃癌的对比研究

Retrospective study on docetaxel plus S-1 versus oxaliplatin plus S-1 in patients with advanced gastric cancer

目的:比较多西他塞(TXT)与奥沙利铂(L-OHP)分别联合替吉奥(S-1)治疗晚期胃癌的有效性和安全性。方法:54例晚期胃癌患者分为两组,A组(TXT+S-1)30例,TXT 75mg/m2静滴2h,d1;S-1 80mg分早晚2次餐后服用,d1-d14;B组(L-OHP+S-1)24例,L-OHP 130mg/m2静滴2h,d1;S-1 80mg分早晚2次餐后服用,d1-d14。两组均3周为1周期,2个周期评价疗效及毒性,随访疾病进展时间和生存期。结果:A、B两组的有效率分别为46.6%和54.2%,疾病控制率为70%和75%,中位疾病进展时间为6.6个月和6.8个月,中位生存时间为13.5个月和14.0个月,差异均无统计学意义(P>0.05)。两组毒副反应主要包括血液学毒性、肝肾功能异常、恶心呕吐、腹泻、末梢神经毒性和过敏反应等,以1-2级为主,均可耐受。结论:TXT联合S-1与L-OHP联合S-1治疗晚期胃癌的疗效相当,不良反应均可耐受。

Objective：To evaluate the efficacy and toxicity of oxaliplatin（L-OHP） or docetaxel（TXT） combined with S-1 in patients with advanced gastric cancer.Methods：All 54 patients with advanced gastric cancer were enrolled and divided into two groups.Group A（TXT＋S-1）：30 patients received TXT of 75mg/m2 on day 1 and S-1 of 80mg orally twice daily after meal on day 1 to 14,every 3 weeks.Group B（L-OHP ＋ S-1）：24 patients received L-OHP 130 mg/m2 on day 1 and S-1 80mg orally twice daily after meal on day 1 to 14,every 3 weeks.Assessment of response was performed every two cycles according to RECIST criteria.The time to progress and overall survival were observed.Results：In group A and group B,the response rates（RR） were 46.6 % and 54.2% respectively,the disease control rates（DCR） were 70% and 75%,the median time to progress were 6.6 and 6.8 months,and the median overall survival（OS） were 13.5 and 14.0 months.There was no significant difference between group A and group B（P0.05）.Side effects in the two groups were similar and well tolerated.Conclusion：TXT plus S-1 and L-OHP plus S-1 are active therapeutic equivalence and well tolerated in patients with advanced gastric cancer.